Small molecules have long been the foundation of modern medicine, accounting for over 90% of all approved drugs.
They offer unmatched flexibility in addressing a broad range of diseases. Yet despite the massive potential — with over 10⁶⁰ oral drug-like compounds theoretically possible — turning a molecular idea into a safe, effective therapy remains one of the hardest challenges in biotech.
At SBH Sciences, we’ve spent 28 years immersed in drug discovery. We’ve seen the field evolve, and we’ve evolved with it.
Computational chemistry and in silico drug design are advancing rapidly. These methods bring speed and scale — from de novo molecule generation to toxicity prediction. But the excitement around digital drug discovery often overlooks one essential truth: predictions are not proof.
The leap from a promising computational model to a validated therapeutic is steep. Real-world biology is complex. Predicted hits rarely behave the same once they enter a cell or system. That “digital-to-wet-lab” gap is where many projects stall.
At SBH Sciences, we’re the execution arm that moves your small molecule from theoretical hit to validated lead. Our lab is where molecules meet biology — and where promising concepts become actionable compounds.
We combine advanced computational insights with rigorous experimental workflows, built to minimize risk and accelerate development. From assay development to DMPK, we support every stage of the discovery process with deep scientific rigor.
